Genomic Health (NASDAQ:GHDX) issued an update on its FY 2018 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.03-1.08 for the period, compared to the Thomson Reuters consensus estimate of $0.53. The company issued revenue guidance of $389-391 million, compared to the consensus revenue estimate of $380.91 million.
Shares of Genomic Health stock traded down $0.18 during trading hours on Tuesday, reaching $70.79. The stock had a trading volume of 228,530 shares, compared to its average volume of 265,318. The company has a market cap of $2.61 billion, a P/E ratio of 7,079.00 and a beta of 0.44. Genomic Health has a twelve month low of $26.54 and a twelve month high of $73.95.
A number of research analysts have weighed in on GHDX shares. Zacks Investment Research downgraded shares of Genomic Health from a strong-buy rating to a hold rating in a research report on Tuesday, July 24th. Piper Jaffray Companies upped their price objective on shares of Genomic Health from $34.00 to $50.00 and gave the stock a neutral rating in a research report on Friday, July 27th. Jefferies Financial Group reiterated a hold rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Friday, August 3rd. Canaccord Genuity upped their price objective on shares of Genomic Health from $56.00 to $62.00 and gave the stock a buy rating in a research report on Friday, August 3rd. Finally, Cowen reiterated a hold rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Monday, August 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. Genomic Health currently has an average rating of Hold and a consensus price target of $46.11.
In other news, CFO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Wednesday, October 10th. The shares were sold at an average price of $63.19, for a total transaction of $315,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kimberly J. Popovits sold 25,000 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $66.26, for a total transaction of $1,656,500.00. The disclosure for this sale can be found here. Insiders have sold 199,279 shares of company stock valued at $12,083,105 in the last three months. Corporate insiders own 45.80% of the company’s stock.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/genomic-health-ghdx-releases-fy-2018-earnings-guidance.html.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Featured Article: Buyback For Investors Defined
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.